The AdjuTec projects have attracted €10mill in private investments and public grants to support R&D activities. The funding has taken our lead product APC148 through preclinical development, preparing a clinical trial submission for our lead compound APC148 early 2024.

AdjuTec will grow company value by funding early-stage clinical programs of pipeline projects. We will then partner with global companies to fund late-stage R&D and for distribution of products.

AdjuTec is entering a high-growth, global market. The global β-lactam and β-lactamase inhibitors market size was €22 billion in 2018, and is projected to reach €28 billion by 2028, growing at a growth rate of 2.3% from 2019 to 2028 [1]. 10% of hospital patients and 30% of intensive-care-unit patients will contract a bacterial infection in hospitals, making healthcare-associated infections (HAIs) a key focus of our technology.

The global marketplace for HAIs caused by Gram-negative bacteria across the seven major pharmaceutical markets (US, EU4, UK and Japan) is projected to exceed €3 billion in sales by 2026, at a growth rate of 10.8% from 2016–2026, [2] representing opportunities for both APC148 and APC247.